Molnupiravir To Reach 105 LMICs Through MPP Agreement

Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral

Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.

Molnupiravir capsules next to bottle
Molnupiravir will be supplied to 105 LMICs through the scheme • Source: Alamy

The Medicines Patent Pool has signed agreements with 27 generics manufacturers to supply oral COVID-19 medication molnupiravir to 105 low- and-middle-income countries (LMICs). The sublicense agreements are the result of the voluntary licensing agreement signed by the MPP and Merck Sharp & Dohme in October last year to facilitate affordable global access to molnupiravir.

Molnupiravir received emergency use authorization from the US Food and Drug Administration in December to treat mild-to-moderate COVID-19 in adults deemed to be at high risk for progression to severe...

More from International

More from Geography

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.